CN116261468A - 治疗急性肾损伤的方法和组合物 - Google Patents

治疗急性肾损伤的方法和组合物 Download PDF

Info

Publication number
CN116261468A
CN116261468A CN202180059383.8A CN202180059383A CN116261468A CN 116261468 A CN116261468 A CN 116261468A CN 202180059383 A CN202180059383 A CN 202180059383A CN 116261468 A CN116261468 A CN 116261468A
Authority
CN
China
Prior art keywords
calcium
inhibitor
aki
pyrazol
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059383.8A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼思·A·斯陶德曼
迈克尔·杜恩
苏达山·赫巴尔
雷切尔·莱尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calcimedica Inc
Original Assignee
Calcimedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcimedica Inc filed Critical Calcimedica Inc
Publication of CN116261468A publication Critical patent/CN116261468A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180059383.8A 2020-05-20 2021-05-19 治疗急性肾损伤的方法和组合物 Pending CN116261468A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027800P 2020-05-20 2020-05-20
US63/027,800 2020-05-20
PCT/US2021/033237 WO2021236820A1 (en) 2020-05-20 2021-05-19 Methods and compositions for treating acute kidney injury

Publications (1)

Publication Number Publication Date
CN116261468A true CN116261468A (zh) 2023-06-13

Family

ID=76444616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059383.8A Pending CN116261468A (zh) 2020-05-20 2021-05-19 治疗急性肾损伤的方法和组合物

Country Status (7)

Country Link
US (1) US20230226058A1 (enExample)
EP (1) EP4153179A1 (enExample)
JP (1) JP2023526505A (enExample)
CN (1) CN116261468A (enExample)
AU (1) AU2021273811A1 (enExample)
CA (1) CA3179405A1 (enExample)
WO (1) WO2021236820A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ，インク． Ｃｒａｃチャネル阻害剤の合成の改善

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530333A (zh) * 2015-02-27 2018-01-02 钙医学公司 胰腺炎治疗
WO2020072942A1 (en) * 2018-10-04 2020-04-09 The Trustees Of Indiana University Methods to treat renal disorders using calcium channel inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078995A2 (en) 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
CN107207431B (zh) * 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530333A (zh) * 2015-02-27 2018-01-02 钙医学公司 胰腺炎治疗
WO2020072942A1 (en) * 2018-10-04 2020-04-09 The Trustees Of Indiana University Methods to treat renal disorders using calcium channel inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLER J, BRUEN C等: ""An Open-Label, Dose-Response Study of CM4620-Injectable Emulsion in Emergency Department Patients With Acute Pancreatitis"", 《ANNALS OF EMERGENCY MEDICINE》, 1 October 2019 (2019-10-01), pages 138 *

Also Published As

Publication number Publication date
CA3179405A1 (en) 2021-11-25
WO2021236820A1 (en) 2021-11-25
JP2023526505A (ja) 2023-06-21
AU2021273811A1 (en) 2022-12-22
EP4153179A1 (en) 2023-03-29
US20230226058A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP7783371B2 (ja) 膵炎処置
JP7066768B2 (ja) 細胞内カルシウムを調節する化合物
US20230226058A1 (en) Methods and compositions for treating acute kidney injury
ES2902073T3 (es) Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia
JP7297827B2 (ja) Ｃｆｔｒ制御因子及びこの使用方法
WO2017027400A1 (en) Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
US20120164102A1 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
CN115835878A (zh) 治疗急性肺损伤和急性呼吸窘迫综合征的方法和组合物
KR20240116482A (ko) 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
US20250120969A1 (en) Methods and compositions for treating inflammation injury in the lungs
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
WO2021116259A1 (en) Aromatic amido derivatives as lpa receptor 2 inhibitors
US20240058315A1 (en) Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
WO2026096796A1 (en) Methods for treating acute pancreatitis
HK40091216A (en) Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
HK1244686B (en) Pancreatitis treatment
JP2002097139A (ja) オキシイミノアルカン酸誘導体の結晶を含有する医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination